Akili Pays $37.5M To License Tali’s Tech For Early Childhood Attention Impairments
Executive Summary
Tali’s video game assesses and improves attention in children three to eight years old. Akili markets the EndeavorRx prescription video game therapy to improve attention function in children ages eight to 12. The deal will help Tali commercialize its technology in the US.
You may also be interested in...
Digital Health Roundup, August/September 2021: Record Digital Health Funding Q1-3 Of $21.3Bn, AAOS Highlights, Regulatory Updates
In this roundup of developments in digital health, we highlight the key news and announcements from August and September.
Winners: Digital Health Companies Noom, Akili, Hello Heart Scored New Funding
Akili Interactive, Hello Heart and Noom announced new funding rounds today, proving that investors’ strong appetite for companies that are part of the digital transformation in health care.
Gaming For Attention: FDA Grants De Novo For Novel ADHD Treatment
A new video game pediatric ADHD treatment has opened the door for other such novel therapies to come to market using the less stringent 510(k) pathway, as interest in such products have gained significant steam over the past few years.